DOPA Formulations for Treatments of Parkinson's Disease
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsMohamed Ahmed, Jayakumar Rajadas, Mohammed Inayathullah Nazir Ahmed, Wenchao Sun
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for preventing and treating dyskinesia, such as drug-induced dyskinesia in patients of Parkinson's disease. The compositions, preferably in a sustained release formulation, include L-DOPA, carbidopa, and ranitidine wherein the weight ratio of L-DOPA to carbidopa is in the range of about 1:(0.2-0.3), or include L-DOPA, benserazide, and ranitidine, wherein the weight ratio of L-DOPA to benserazide is in the range of about 1:(0.4-0.6).
Claims20
A formulation, comprising L-DOPA, a decarboxylase inhibitor, and ranitidine dispersed in a polymer.
A method of preventing or treating dyskinesia in a patient suffering from Parkinson's disease (PD), comprising administering to the patient an effective amount of a formulation comprising L-DOPA, a decarboxylase inhibitor, and ranitidine dispersed in a polymer.
Dependencies are inferred from the claim text.